Immune-related Encephalitis in Two Patients Treated With Immune Checkpoint Inhibitor

被引：9
|
作者：
Robert, Lucie [1 ,2 ]
Langner-Lemercier, Sophie [3 ]
Angibaud, Alexis [1 ]
Sale, Alexandre [1 ]
Thepault, Fanny [4 ]
Corre, Romain [1 ,5 ]
Lena, Herve [1 ,5 ]
Ricordel, Charles [1 ,5 ]
机构：
[1] CHU Rennes, Resp Med Dept, Rennes, France
[2] CLCC Eugene Marquis, Serv Oncol Med, Rennes, France
[3] CHU Rennes, Neurol Dept, Rennes, France
[4] CH St Malo, Resp Med Dept, St Malo, France
[5] CLCC Eugene Marquis, Chem Oncogenesis Stress & Signaling, INSERM, U1242, Rennes, France
来源：
CLINICAL LUNG CANCER | 2020年 / 21卷 / 05期
关键词：
Atezolizumab; Immune encephalitis; Immune-related adverse events; NSCLC; Nivolumab; NEUROLOGICAL TOXICITIES; IPILIMUMAB; MELANOMA;
D O I：
10.1016/j.cllc.2020.03.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E474 / E477
页数：4
相关论文
共 50 条
  • [41] Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review
    Abdel-Rahman, Omar
    Eltobgy, Mostafa
    Oweira, Hani
    Giryes, Anwar
    Tekbas, Aysun
    Decker, Michael
    IMMUNOTHERAPY, 2017, 9 (14) : 1175 - 1183
  • [42] Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
    Jingting Wang
    Yan Ma
    Haishan Lin
    Jing Wang
    Bangwei Cao
    BMC Immunology, 25
  • [43] Racial disparities in immune-related adverse events in patients with lung cancer treated with immune checkpoint inhibitors
    Chandani, K. Uttam
    Agrawal, S.
    Raval, M.
    Khan, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1176 - S1176
  • [44] Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors
    Serino, M.
    Freitas, C.
    Martins, M.
    Ferreira, P.
    Cardoso, C.
    Veiga, F.
    Santos, V.
    Araujo, D.
    Novais-Bastos, H.
    Magalhaes, A.
    Queiroga, H.
    Fernandes, G.
    Hespanhol, V.
    PULMONOLOGY, 2024, 30 (04): : 352 - 361
  • [45] MUSCULOSKELETAL IMMUNE-RELATED ADVERSE EVENTS IN 927 PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS FOR SOLID CANCER
    Melia, A.
    Fockens, E.
    Madroszyk, A.
    Lafforgue, P.
    Pham, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 184 - 185
  • [46] Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy
    Chen, Gang
    Wang, Lin
    Diao, Tongwei
    Chen, Ying
    Cao, Chengbo
    Zhang, Xindong
    ONCOLOGY LETTERS, 2020, 20 (01) : 517 - 524
  • [47] Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
    Wang, Jingting
    Ma, Yan
    Lin, Haishan
    Wang, Jing
    Cao, Bangwei
    BMC IMMUNOLOGY, 2024, 25 (01)
  • [48] Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer
    Melia, Angelique
    Fockens, Emilie
    Sfumato, Patrick
    Zemmour, Christophe
    Madroszyk, Anne
    Lafforgue, Pierre
    Pham, Thao
    JOINT BONE SPINE, 2023, 90 (01)
  • [49] Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors
    Gault, A.
    Anderson, A. E.
    Plummer, R.
    Stewart, C.
    Pratt, A. G.
    Rajan, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 263 - 271
  • [50] Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
    Les, Inigo
    Martinez, Mireia
    Perez-Francisco, Ines
    Cabero, Maria
    Teijeira, Lucia
    Arrazubi, Virginia
    Torrego, Nuria
    Campillo-Calatayud, Ana
    Elejalde, Inaki
    Kochan, Grazyna
    Escors, David
    CANCERS, 2023, 15 (05)
12345